profit from every $100 of sales.
$0$100
NervGen Pharma
$1.35+1.50% today
-68.4% in 1 year
1-year low $1.321-year high $5.97
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What NervGen Pharma sold, what it kept, and what it did with the cash.
Sales went from CA$0 in 2022 to CA$0 in 2025, with -CA$44.1 million of profit last year.
SalesProfit
NervGen Pharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| NervGen Pharma | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads NervGen Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -23 | -18 | -25 | -25 | |
| -20 | -18 | -25 | -25 | |
| -21 | -22 | -24 | -44 | |
| -0.39 | -0.38 | -0.36 | -0.61 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 24 | 13 | 19 | 23 |
| Cash | 22 | 12 | 17 | 22 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 10 | 15 | 17 | 20 |
| 13 | -2 | 3 | 3 | |
| 53 | 59 | 67 | 72 | |
| -116.1% | – | -741.5% | -568.5% | |
| -153.9% | 1,114.0% | -941.2% | -1,268.9% |
Cash flow
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -18 | -11 | -17 | -19 | |
| 0 | 0 | – | – | |
| -18 | -11 | -17 | -19 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 3 | 6 | 6 | 5 |
Valuation
- –
- –
- –
- 108.4×
- –
- –
- –
- -6.9%
- -15.5%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -719.6%
- -230.4%
- -17,536.8%
- -190.1%
- -721.3%
- –
Growth
- –
- –
- −66.6%
- –
- +16.5%
Financial health
- 0.9×
- 0.00
- 0.0%
- –
- 1.16
- 1.16
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 889
Bottom 14%of 987
What analysts expect
- Average price target
- $12.00
- Range
- $12.00 – $12.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 18, 2026 | -0.07 | -0.07 | +11.5% |
| Mar 31, 2026 | -0.26 | -0.11 | −125.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
13No pass
Benjamin Graham
38No pass
Philip Fisher
28No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
25No pass
Questions about NervGen Pharma
Is NervGen Pharma a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the NervGen Pharma AI analysis
What does NervGen Pharma do?
NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting mechanisms that inhibit nervous system repair. It is in Biotechnology.
Does NervGen Pharma pay a dividend?
No. NervGen Pharma does not pay a dividend at the moment.
Is NervGen Pharma stock halal?
Yes. NervGen Pharma passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has NervGen Pharma stock done over the past year?
Down 68.4% over the past twelve months, to $1.35. It traded between $1.32 and $5.97 and is 77.4% below its high.
Who are NervGen Pharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with NervGen Pharma's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.